AzTrials
AzTrials

DiabetesNCT01297387

Feasibility of Peripheral Angioplasty in Type D TASCII Lesions

An observational study of Diabetes and Critical Limb Ischemia, run by IRCCS Multimedica at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This observational prospective study will evaluate, according o usual local clinical practice, feasibility of endoluminal revascularization in diabetic patients with type C and D lesions, according to TASC II Criteria. About 300 patients will be treated with usual revascularization procedure. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diabetes, Critical Limb Ischemia
What is being tested?
PTA BPG procedure,
How many people
344 participants
Where
1 siteItaly
Study dates
Jan 2009to Dec 2009
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Diabetic patients with critical limb ischemia

Who may be able to join

  • Adult diabetic patients type 1 or 2
  • Chronic critical ischemia as defined by TASC 2007 criteria (pain at rest, and/or ulcer or gangrene due to arteriopathy: transcutaneous oximetry < 30 mmHg or pressure on the ankle < 70 mmHg)

Who cannot join

  • Cancer with adverse prognosis in months, or chemotherapeutic treatment
  • Ongoing or planned pregnancy
  • Lack of consent to participate to the study

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Diabetic Foot Center IRCCS MultiMedica

    Sesto San Giovanni, Milano, 20099

Other trials in Italy

About this study

Official title: An Observational, Prospective Study Evaluating Feasibility of Peripheral Angioplasty in Diabetic Patients With Critical Limb Ischemia in C and D Obstructions of Transatlantic Inter-Society Consensus (TASC II).

This observational prospective study will evaluate, according o usual local clinical practice, feasibility of endoluminal revascularization in diabetic patients with type C and D lesions, according to TASC II Criteria.

About 300 patients will be treated with usual revascularization procedure. Each patient will be followed at least 12 months to evaluate clinical outcome and limb salvage interventions.

Read the detailed description

In 2000, the Trans Atlantic Inter-Society Consensus (TASC) stated that patients with CLI should be treated with revascularization, to provide sufficient blood flow to relieve the rest pain and heal skin lesions. TASC also suggested that the best procedure should avoid a general anaesthesia, pose a lesser systemic stress and have fewer serious complications.

All these considerations pose peripheral angioplasty (PTA) as the procedure of choice, when feasible.

Unfortunately, TASC Recommendations, published in 2000 and confirmed in 2007, use morphological criteria to define guidelines for the choice of revascularization procedure.

According to these recommendations, type C and D lesions, which comprise most serious stenosis and occlusions, affecting long tracts of vessels, are candidate to bypass interventions, more than PTA.

This choice was due to the first impression, then denied by BASIL study, that PTA could be affected by a reduced efficacy on limb salvage.

Diabetic Patients are characterized by high prevalence of long occlusions in crural arteries and this anatomical asset reduces, according to TASC II criteria, the feasibility of Bypass Graft (BPG) in a large number of such patients.

Our preliminary experience showed the feasibility of PTA in diabetic patients with Chronic Critical Limb Ischemia (CLI), with a high percentage of efficient revascularization, regardless of morphology and number of obstructions.

This study aims to evaluate outcomes after PTA procedure also in patients with lesions of 20 cm or longer in superficial femoral arteries or with "long lesions" in subpopliteal arteries.

All diabetic patients referring to our Diabetic Foot Centre either for foot lesions or rest pain will be assessed for the presence of Critical Limb Ischemia (CLI) according to TASC II Criteria.

These patients, according to usual local clinical practice, will undergo to angiographic evaluation and, if feasible, to peripheral angioplasty.

The peripheral pulses will be evaluated by palpation and auscultation with a continuous-wave Doppler technique, the ankle-pressure will be recorded, when assessable (foot arteries absent or not compressible because of medial calcifications), the transcutaneous oxygen tension (TcPO2) will be evaluated at the dorsum of the foot and a duplex scanning will be performed. In all patients with one reduced or absent foot pulse, TcPO2 < 50 mmHg, ankle-pressure < 70 mmHg, significant obstructions present at duplex scanning, an arteriography will be carried out. In all patient with obstruction > 50% of vessel diameter, PTA will be the first-choice revascularization procedure and will be performed in the same session of the angiographic study. In patients in whom PTA will not be feasible, a by-pass operation was considered. The patients in whom PTA or BPG were not possible, received a therapy with prostanoids or lumbar sympathectomy plus prostanoids, when possible. In patients in whom the therapies did not relieve the rest pain or the gangrene was extended above the Chopart joint, an above-the-ankle-amputation was proposed and performed.

PTA procedure PTA was considered indicated for angiographically documented obstructions greater than 50% of the vessel lumen. The procedures were performed under local anesthesia through antegrade puncture of the ipsilateral common femoral artery. If obstructions were present in the iliac trunk at duplex scanning, the puncture was performed by contralateral approach. Vessel recanalization was considered successful when direct flow was obtained in treated vessel, with no residual stenosis > 50% of vessel diameter along the artery.

BPG procedure The choice of proximal and distal BPG anastomoses depended on the angiographic picture and aimed at obtaining at least one patent foot artery. The inflow was optimized, when possible, by combining femoral-popliteal bypass and PTA of the iliac trunk. Moreover, also in view of a following distal angioplasty, the distal anastomosis was performed on the most suitable popliteal or tibial artery segment by using intraluminal clamping and microsurgical technique. The surgery has always been carried out under epidural anesthesia. The autogenous saphena vein was employed if present and in good condition. If venous conduit could not be used, alloplastic prosthetic material (polytetrafluoroethylene: PTFE) was employed and the peripheral below-the-knee anastomosis consisted of a venous cuff using the Miller's technique, or "composite" bypass with interposition of distal venous segments. The absence of an available saphena and an angiographic score of run off >7 on the Rutherford scale did not exclude any patient, who otherwise could be eligible only for a major amputation, from a revascularization with distal bypass.

Treatment of non revascularized patients Prostanoids (alprostadil-α-cyclodextrine 60-120 μgr/day) were infused intravenously on average 5 days before hospital discharge. When possible and accepted by the patients, lumbar sympathectomy was performed.

In all patients the pain change was recorded and the TcPO2 and ankle-pressure values were reassessed 5 days after the PTA, BPG, lumbar sympathectomy and medical therapy.

Limb salvage In patients complaining of rest pain without foot ulcer, the disappearance of pain was considered to be a successful limb salvage. In patients with foot ulcer we considered limb salvage successful when the ulcer was healed and plantar stand was maintained, even when achieved by tarsal-metatarsal amputation and the patient is able to walk without crutches or artificial leg. Conversely, any above-the-ankle amputation was considered a failure. Limb salvage was considered early when pain disappeared and ulcer healed in 30 days after hospital admission.

Follow-up After hospital discharge All the patients with foot ulcer were examined weekly until ulcer healing. All patients were provided with extra-deep rocker shoes with soft thermoformable leather and customized insoles.

Evidence of PTA restenosis was assessed clinically only, based on pain reappearance or ulcer recurrence. In these situations ankle-pressure and TcPO2 were reassessed and duplex scanning was performed (22). If ankle pressure and TcPO2 were significantly worse (<15% of the post-PTA value) and Duplex scanning was positive, the patient underwent a repeated angiographic evaluation and a further PTA, if possible. Morphological restenosis was not investigated: in absence of rest pain or ulcer reappearance we do not perform any revascularization (23), therefore we consider the morphological restenosis clinically irrelevant.

BPG treated patients were followed with vascular surgery protocol (24). The graft patency was assessed with clinical examination and ultrasound study at 30 days, 3,6,12 months and thereafter every 6 months. Pulse systolic velocity and anastomosis morphology were assessed by ultrasound study. Finally, inflow is compared with pre-operative condition.

For every invasive treatment (PTA, BPG, sympathectomy, surgical operation on the foot) the written informed consent form was proposed and obtained from the patient.

Being tested
PTA BPG procedure,
Keywords
Diabetic Patients, Critical Limb Ischemia, Revascularization
Medical subject headings
Diabetes Mellitus, Chronic Limb-Threatening Ischemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PTA BPG procedure,Other

    Also called Peripheral angioplasty

    Surgery PTA or BPG Procedure, according usual local clinical practice

Study groups in NCT01297387
Study groupRoleWhat they receive
Revascularization of limb ischemiaProcedure/Surgery
Receives: Other: PTA BPG procedure,

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Feb 2011 (estimated)
  2. Study startJan 2009
  3. Study completionDec 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
344 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01297387
Sponsor's protocol ID
08/2007_Cardiovascolare
Status last verified
Feb 2011
First submitted
15 Feb 2011
Last updated
21 Feb 2011
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes and Critical Limb Ischemia, run by IRCCS Multimedica at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Feb 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in